Sibutramine
- TRADE NAME: Meridia (AbbVie)
- INDICATIONS: Obesity
- CLASS: Norepinephrine antagonist, Serotonin antagonist
- HALF-LIFE: 1.1 hours
Amitriptyline, Citalopram, Desvenlafaxine, Dextromethorphan, Dihydroergotamine, Duloxetine, Ephedra, Ergot, Fluoxetine, Fluvoxamine, Isocarboxazid, Linezolid, Lithium, MAO inhibitors, Meperidine, Methysergide, Milnacipran, Naratriptan, Nefazodone, Paroxetine Hydrochloride, Phenelzine, Rizatriptan, Sertraline, Sumatriptan, Tapentadol, Tranylcypromine, Tryptophan, Venlafaxine, Verapamil, Zolmitriptan, Zuclopenthixol
PREGNANCY CATEGORY: C
Due to an increased risk of heart attack and stroke in patients with cardiovascular disease, sibutramine should not be used in patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke.
Sibutramine has been withdrawn in the USA and the European Union due to risk of serious cardiovascular events.
Please login to see the rest of this drug profile
Page last updated 07/31/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
